ライフサイエンスコーパス: viremic

1 ere infected with HCV and 4,728 (81.8%) were viremic.

2 subsequent RNA testing revealed that 3 were viremic.

3 en aged <10 years hospitalized with CAP were viremic.

4 oculated orally-nasally, became persistently viremic.

5 llected at enrollment and were classified as viremic.

6 s in feces; two seroconverted and one became viremic.

7 nd in horses worldwide with approximately 3% viremic.

8 eir HIV infection and 2,816 (69.5%) were HIV viremic.

9 imal by 20 weeks, the second animal remained viremic (103 to 107 genome equivalents per ml) for >2 ye

10 sk needlestick injury but nonetheless became viremic 11 weeks later.

11 oscleral rims from 4 patients: 1 patient was viremic, 2 were viremic and IgM positive, and 1 was IgM

12 all anti-HCV-positive cases), 175 (61%) were viremic (3.8% overall prevalence in cohort), which was 5

13 re unaware of their status and those who are viremic across 26 Indian cities at various epidemic stag

14 All infected horses became viremic after 1 or 2 wk and viremia could be detected in

15 The main group of 346 lead-in nonresponders (viremic after 24 weeks of peginterferon-ribavirin therap

16 9 on ADV-TDF), and for patients who remained viremic after the addition of FTC (7/20 on TDF and 5/14

17 dy, we dissected the function of NK cells in viremic and aviremic HIV-1-infected subjects, as well as

18 with peripheral blood mononuclear cells from viremic and aviremic HIV-infected subjects.

19 was evaluated in B cells from HIV-1-infected viremic and aviremic subjects and healthy subjects, in c

20 The fourth animal remained viremic and died at week 47.

21 e I interferon (IFN) receptor (IFNAR) became viremic and died of infection after a high-dose vaginal

22 subjects who were HCV seronegative, both HCV viremic and HCV aviremic individuals were at increased r

23 om 4 patients: 1 patient was viremic, 2 were viremic and IgM positive, and 1 was IgM positive.

24 in peripheral blood mononuclear cells of all viremic and many nonviremic animals.

25 .9%) had anti-HCV antibodies, 54 (2.1%) were viremic and of those, 52 (2.1%) agreed to IL28B testing.

26 pigs shed the virus in feces; two pigs were viremic and seroconverted to anti-HEV.

27 seropositive or viremic animals, five became viremic and three died with anemia.

28 Twenty-four patients (7.6%) became viremic and three patients (1%) developed polyoma virus

29 Animals were viremic and viral antigen was first observed in multiple

30 pecimens from 12 donors who were or were not viremic and were or were not seropositive were investiga

31 Twelve apparently uninfected donors were viremic and/or positive for immunoglobulin M (IgM) and/o

32 h chronic HBV infection (118 aviremic and 67 viremic) and compared them with pDCs from uninfected ind

33 A total of 52 602 HCV seronegative, 9508 HCV viremic, and 913 HCV aviremic subjects were included.

34 l, 57 of 570 (10%) RV-positive patients were viremic, and all were children aged <10 years (n = 57/37

35 ipients of donor tissue from seropositive or viremic animals, five became viremic and three died with

36 Of the 11 acutely viremic animals, five were euthanized because of severe

37 udies--Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (M

38 evels of plasma IFN-alpha/beta were found in viremic ART-treated and control subjects.

39 nt proportion (22%) of patients who were HIV viremic at baseline had undetectable HIV RNA at week 12.

40 of HCV infection from cardiac donors who are viremic at the time of organ donation occurs with high f

41 virus (HCV) recurrence in recipients who are viremic at time of liver transplantation (LT) is univers

42 infection recurs in liver recipients who are viremic at transplantation.

43 The transfected chimpanzee became viremic at week 2, and recovered viruses had the chimeri

44 For patients who are still viremic at week 4, treatment durations even longer than

45 ent disease is universal in patients who are viremic before transplantation.

46 , mosquitoes become infected when feeding on viremic birds and subsequently transmit the virus to sus

47 s) and those with mild (virurics) or severe (viremics) BKPyV reactivation after graft receipt.

48 PBMC from 69 aviremic and 56 viremic blood donors were then analyzed for the presence

49 ing West Nile virus (WNV) infection, acutely viremic blood donors, identified by nucleic acid amplifi

50 tion can be assessed by follow-up studies of viremic blood donors.

51 o DENV infection when fed on patient-derived viremic blood meals.

52 ect persons with acute HIV infection who are viremic but antibody-negative.

53 Nine patients and 1 healthy volunteer were viremic but had seronegative test results for JCV antibo

54 us dendritic cells (DCs) from HIV-1-infected viremic but not aviremic individuals are markedly impair

55 Moreover, mDCs generated from HIV-1 viremic but not aviremic patients are substantially impa

56 es were detected in 13 (92.86%) of 14 HPgV-2-viremic cases, and NS4AB antibodies were detected in 8 (

57 most with similar inflammatory infiltrate to viremic cases.

58 ion index, 20), in contrast with only 1 of 9 viremic children (median p24 stimulation index, 2.0; p =

59 hildren (P = .002) and in the 3 seronegative viremic children (P = .025).

60 Dengue transmission risk was high near viremic children in both high- and low-incidence years.

61 mature NK cells were significantly lower in viremic children with a history of decreasing CD4+ cell

62 Compared with the 5 seropositive viremic children, the median number of HCV-specific spot

63 th viral loads (VL) of <400 on HAART, and 12 viremic children.

64 4 expression was increased on B cells of HIV-viremic compared with HIV-aviremic and HIV-negative indi

65 iring various aspects of NK cell function in viremic condition, and several viral factors contribute

66 ting expression of one bNAb produced durable viremic control after ART was terminated.

67 inued emphasis by HIV care providers on both viremic control and preventive measures including smokin

68 y potent bNAbs not only resulted in complete viremic control but also led to a reduction in cell-asso

69 n of ART and immunotherapy enabled prolonged viremic control by a single bNAb after ART was withdrawn

70 s in HIV-1YU-2-infected humanized mice, with viremic control exhibited when a third antibody, 10-1074

71 significantly more strongly associated with viremic control than HLA-B*14:01.

72 rval [CI], 58-93 days), and the mean rate of viremic control was -0.66 log(10) VL per month.

73 viduals with protective HLA class I alleles, viremic control was associated with broad CD8(+) T cells

74 Within elite and viremic controller groups, those with protective class I

75 of a patient with progressive disease and a viremic controller.

76 sequence diversity analysis in the plasma of viremic controllers (<50-2000 copies RNA/mL).

77 95% confidence interval {CI}, 0.35%-0.80%]), viremic controllers (ie, subjects with plasma HIV RNA le

78 rs (n = 16; viral load [VL], <75 copies/ml), viremic controllers (n = 14; VL, 75 to 2,000 copies/ml),

79 nd Pol peptides was highest in the elite and viremic controllers (P < 0.0001).

80 Viremic controllers and elite controllers/suppressors ma

81 These data suggest that some viremic controllers and elite suppressors are infected w

82 HLA-B*57 compared to twenty-three percent of viremic controllers and nine percent of noncontrollers (

83 In viremic controllers and progressors, we found variant re

84 Viremic controllers showed significantly broader mucosal

85 we show that CD8(+) T cells from 2 out of 4 viremic controllers were capable of effectively eliminat

86 In contrast, viremic controllers without protective HLA class I allel

87 ontrollers" (viral load < 75 copies/mL), 11 "viremic controllers" (75-2000 copies/mL), 14 noncontroll

88 64), those with levels of 50-2000 copies/mL (viremic controllers, n = 60); we also examined HIV-speci

89 For elite and viremic controllers, spontaneous virologic control was e

90 d more-stable CD4 cell trends, compared with viremic controllers.

91 iduals receiving antiretroviral therapy, and viremic controllers.

92 elite controllers (HIV-RNA < 75 copies/ml), "viremic" controllers (low-level viremia without therapy)

93 background), when directly blood-fed on 141 viremic dengue patients, have lower dengue virus (DENV)

94 cted subjects who were HCV seronegative, HCV viremic (detectable HCV RNA), or HCV aviremic (HCV serop

95 by minipool testing, yielding 183 confirmed viremic donations (0.027 percent, or 1 in 3703 donations

96 yield data and vice versa, and suggest that viremic donations will be rare relative to clinical dise

97 d in blood donors who made WNV RNA-positive (viremic) donations in 2003.

98 nly observed in recipients of blood from the viremic donor; transfer of SRV provirus and unintegrated

99 total of 84% of the specimens obtained from viremic donors before IgM/IgG seroconversion demonstrate

100 Follow up of 35 additional viremic donors for up to 404 days was conducted to evalu

101 Specimens from 102 viremic donors with and without WNV antibodies were used

102 The 13 viremic donors with no detectable PBMC-associated HCV RN

103 ially so in memory B cells from HIV-positive viremic donors, suggesting a possible underlying mechani

104 ociated HCV RNA was detected in 43 of the 56 viremic donors.

105 -positive IDUs (16 [94%] of 17 IDUs) than in viremic EIA-positive IDUs (9 [45%] of 20 IDUs) (P= .003)

106 samples or necropsy tissue samples from six viremic elephants.

107 36M was identified subsequent to a wild-type viremic episode.

108 000 copies/mL) and minor (50-1000 copies/mL) viremic episodes (VEs) and factors associated with major

109 lly distinct viral variants during recurrent viremic episodes is thought to be due to adaptive immune

110 tic interventions were performed in 59.1% of viremic episodes.

111 by 6 replicate TMA tests; samples that were viremic for >40 days were tested for WNV-neutralizing ac

112 Non-pregnant and pregnant animals remain viremic for 21 days and for up to at least 57 days, resp

113 nge (DPC), 9 out of the 12 group 4 pigs were viremic for PCV2.

114 ts at baseline, and any patient who remained viremic (HBV DNA 400 copies/mL [69 IU/mL]) at week 288 o

115 ription polymerase chain reaction to confirm viremic HCV (V-HCV) infection.

116 ith a cohort of post-OLT and nontransplanted viremic HCV patients, the index patient with HCV clearan

117 dependent, and this activity was impaired in viremic HIV infection but not in HCV infection.

118 s closely associated with killer activity in viremic HIV infection but not in healthy controls.

119 irect IFN-alpha stimulation was defective in viremic HIV infection, and this defect was not attributa

120 endent on PDC and NK cells) were impaired in viremic HIV infection.

121 ated inversely with plasma HIV RNA levels in viremic HIV patients.

122 miniscent of that described in patients with viremic HIV was detected.

123 ion with IL-7, however, was diminished among viremic HIV(+) donors and occurred independent of antige

124 ) expression was seen in CD4(+) T cells from viremic HIV(+) subjects compared to controls or followin

125 ood ILCs were severely depleted during acute viremic HIV-1 infection and that ILC numbers did not rec

126 Taken together, these data demonstrate that viremic HIV-1 infection is associated with a reduction i

127 g mechanisms leading to immune activation in viremic HIV-1 infection, however, are not fully understo

128 ss following stimulation with TLR ligands in viremic HIV-1 infection.

129 ysfunction observed during acute and chronic viremic HIV-1 infection.

130 t immune activation is a hallmark of chronic viremic HIV-1 infection.

131 ute to the immune activation observed during viremic HIV-1 infection.

132 ed gene expression in low- versus high-level viremic HIV-1 patients, suggesting a shift in apoptosis

133 on was highly increased in DCs isolated from viremic HIV-1 patients, suggesting that CD8(+) T cells a

134 nal cost a substantial number of unaware and viremic HIV-infected and HCV-infected individuals who we

135 l CD56(dim) NK cells increased in cART-naive viremic HIV-infected individuals (median [interquartile

136 cts in signaling were observed in cells from viremic HIV-infected persons and were especially pronoun

137 e populations are significantly increased in viremic HIV-infected subjects as compared with healthy s

138 Our data indicate that viremic HIV-infected subjects may have different levels

139 ory CD4 T cells isolated from lymph nodes of viremic HIV-infected subjects.

140 cell inhibitory and activating receptors in viremic human immunodeficiency virus (HIV)-infected pati

141 In contrast, 19 (90%) of 21 viremic IDUs displayed neutralizing antibodies (nAbs), c

142 Only 1 of 18 healthy volunteers were viremic in CD34+ cells and none in CD19+ cells.

143 ss, but found a substantial population to be viremic, in need of ART, and at risk for transmission.

144 ents were viruric and 28 (54%) patients were viremic, including 13 with biopsy-confirmed BKVAN.

145 ntibodies to E2 were detected in most HPgV-2-viremic individuals (92.86%), as is observed among indiv

146 an immunodeficiency virus (HIV)-infected and viremic individuals exhibit elevated levels of plasma cy

147 all fraction of plasmablasts in the blood of viremic individuals is HIV specific.

148 minant of the rate of disease progression in viremic individuals is unknown.

149 dysfunctional CD56(-) NK cell subset in HIV-viremic individuals largely accounts for the impaired fu

150 The detection rate of HIV viremic individuals was positively associated with under

151 ion in the absence of HCV viremia, while HCV-viremic individuals who previously were PWID continue to

152 a of HIV-infected individuals, especially in viremic individuals, and correlated with serum immunoglo

153 in levels were also elevated in HIV-infected viremic individuals, especially IgG, and correlated with

154 mber in the peripheral blood of HIV-infected viremic individuals, in whom they are associated with B-

155 lute CD4(+) T cell loss is more common among viremic individuals, suggesting that even very low-level

156 When Tregs are depleted from PBMCs of viremic individuals, the effect of the IL-10 signaling b

157 are maintained at abnormally high levels in viremic individuals.

158 tion of CD4 T helper cells are restricted to viremic individuals.

159 lar B cell subpopulation in the blood of HIV-viremic individuals.

160 ibed a number of NK cell dysfunctions in HIV-viremic individuals.

161 )) NK subset that is greatly expanded in HIV-viremic individuals.

162 f 3BNC117 affects host antibody responses in viremic individuals.

163 HIV-exposed, HCMV-viremic infants were more commonly referred for hospital

164 Viremic infants were more likely to have (1) hearing los

165 tory syndrome virus (PRRSV) causes an acute, viremic infection of 4 to 6 weeks, followed by a persist

166 Viremic infection was common among serologically confirm

167 Ambulatory children with mild febrile viremic infections could represent an important componen

168 mononuclear cells from healthy controls and viremic KTR were stimulated using BK virus peptide libra

169 T cell lines can be reliably generated from viremic KTR.

170 ol to generate BK-specific T cell lines from viremic KTR.

171 w and detect Zika virus from the plasma of a viremic macaque.

172 Accordingly, low-viremic macaques had a higher frequency of both bone mar

173 nfected humans, we examined the plasma of 13 viremic macaques infected with SHIVSF162P3Nand 85 HIV-1-

174 lymphoid tissues and reproductive organs of viremic monkeys.

175 reases of CD8(+) Tregs with increasing VL in viremic monkeys.

176 cination, oral antiviral therapies in highly viremic mothers can further decrease MTCT of HBV.

177 Treatment with TDF for highly viremic mothers decreased infant HBV DNA at birth and in

178 patitis B virus (HBV) transmission in highly viremic mothers remains a global health issue.

179 LdT and LAM use in late pregnancy for highly viremic mothers was equally effective in reducing MTCT.

180 ive at time of donation, but was found to be viremic on retrospective testing.

181 ion on antiretroviral therapy, but not among viremic or untreated HIV-infected women.

182 Viremic participants had elevated liver enzyme levels an

183 Viremic participants were more likely to be women, compa

184 sing M-CSF and GM-CSF, which is increased in viremic patient's plasma.

185 ducted a cross-sectional study of cART-naive viremic patients (ART(-)), virologically suppressed pati

186 Per protocol, viremic patients (HBV DNA level >/= 400 copies/mL or 69

187 C samples showed little variation for either viremic patients (median fold differences of 0.80 and 0.

188 heral blood mononuclear cells (PBMCs) from 5 viremic patients and 20 patients receiving effective ART

189 n by first analyzing monocytes isolated from viremic patients and patients undergoing antiretroviral

190 s, we cloned full-length Envs from plasma of viremic patients and tested their apoptosis-inducing pot

191 tible as or more susceptible than cells from viremic patients and uninfected donors to HIV-1 entry an

192 state of resting CD4(+) T cells in infected viremic patients and, in turn, allows release of HIV-1 w

193 resting CD4(+) T cells from the majority of viremic patients are capable of producing cell-free HIV-

194 formed at the baseline for all patients, for viremic patients at week 144 or at the last time when th

195 IFN-alpha in response to HIV than pDCs from viremic patients but similar levels to pDCs from healthy

196 6(+) intermediate monocytes were elevated in viremic patients compared to those in uninfected control

197 tly upregulated in resting CD4(+) T cells of viremic patients compared to those of aviremic patients.

198 T cells was clearly observed in HIV-infected viremic patients compared with aviremic patients with co

199 The degree of B cell dysfunction in viremic patients correlated strongly with the inability

200 In contrast, pDCs from viremic patients expressed membrane TRAIL without any st

201 Viremic patients had fewer codetected pathogens and were

202 At 12 months, all viremic patients had multiple resistance and compensator

203 In a subset of high viremic patients harboring R5 tropic HIV, there was a st

204 were observed in the B cells of HIV-infected viremic patients in the context of B cell receptor stimu

205 d terminal differentiation in B cells of HIV-viremic patients lead to an increased propensity to cell

206 ivation, the low CD4 expression by pDCs from viremic patients may explain the weak IFN-alpha response

207 The ability to analyze archival species in viremic patients may have clinical utility in detecting

208 Blood mononuclear cells from viremic patients produced more TNFalpha in response to L

209 Characteristics of Vgamma2Vdelta2 T cells in viremic patients reflect both active responses (increasi

210 ly after transplantation, the liver graft of viremic patients universally becomes infected by circula

211 fective B cell costimulatory function in HIV-viremic patients was associated with low induction of CD

212 l sequences from the resting CD4+ T cells of viremic patients were found to be genetically distinct f

213 42 genes were up-regulated in B cells of HIV-viremic patients when compared with HIV-aviremic and HIV

214 232 direct blood-feeding experiments on 118 viremic patients with dengue in Vietnam.

215 TLR9-L-activated pDCs from viremic patients with HBV did not induce cytolytic activ

216 by incubating control pDCs with plasma from viremic patients with HBV.

217 f hepatitis B virus (HBV) e antigen-positive viremic patients with normal liver function and the inco

218 r isolation from the peripheral blood of ES, viremic patients, and uninfected donors.

219 infection: primary HIV infection, long-term viremic patients, aviremic patients treated with highly

220 amma2Vdelta2 T cells were more pronounced in viremic patients, compared with antiretroviral therapy r

221 We also demonstrate that in HIV-infected viremic patients, expression of iNKRs was well conserved

222 In asymptomatic viremic patients, the highest pp65emia and qPCR values w

223 ated that CD21(low) B cells, enhanced in HIV-viremic patients, were largely responsible for the chang

224 response of CD4(+) T cells to B cells of HIV-viremic patients, while the addition of exogenous CD28 l

225 emia and CD4 T-cell depletion in contrast to viremic patients.

226 only five centers would transplant actively viremic patients.

227 persistence of KIR3DS1(+) NK cells in HIV-1 viremic patients.

228 st HIV-1 lab strains than those of untreated viremic patients.

229 pressors than in HAART-treated and untreated viremic patients.

230 e a consequence of high levels of antigen in viremic patients.

231 recapitulating the changes observed for HIV-viremic patients.

232 f viral species in resting CD4+ T cells from viremic patients.

233 CD4(+) T cell response to the B cells of HIV-viremic patients.

234 echanisms of impaired host defenses in HIV-1 viremic patients.

235 CD4 counts and CD4:CD8 ratio specifically in viremic patients.

236 D4RTE percentage (77% vs 81%; P = .003) than viremic patients.

237 Because DENV viremic people without clinical symptoms may be exposed

238 emiology include viremia titer, variation in viremic period, enhanced viremias, and threshold viremia

239 IV-1 latency, reservoir stability, low-level viremic persistence, and emergence of intermittent viral

240 The CVD mortality rate was highest among viremic persons (adjusted rate ratio [RR], 3.53 [95% con

241 responses that are critical during the early viremic phase of CMV infection.

242 V) genotype C is associated with a prolonged viremic phase, delayed hepatitis B e antigen (HBeAg) ser

243 severe disease progression during the acute viremic phase, they cleared the virus faster and did not

244 atment of acute viral myocarditis during the viremic phase.

245 potential harms from steroid use during the viremic phase.

246 ellular target for ZIKV infection during the viremic phase.

247 bility of success if administered before the viremic phase; however, because vascular leakage is asso

248 egulation or hypoferremia during the primary viremic phases of HCV or HBV infection; serum iron margi

249 tion of individual library HCVpp by the last viremic plasma sample obtained before clearance was comp

250 lemented, there is a need to identify acute (viremic preseroconversion) infections and to discriminat

251 HCV viremic prevalence peaked in 1994 at 3.3 (2.8-4.0) milli

252 studied the integration profile of HIV-1 in viremic progressors, individuals receiving antiretrovira

253 envelopes derived from chronically infected viremic progressors.

254 HCV-viremic PWID have elevated levels of immune activation w

255 (Eomes) differentiated LTR controllers from viremic relapsers and reciprocally correlated with granz

256 on differentiated LTR controllers from early viremic relapsers, correlating with granzyme B loading a

257 Three of 10 viremic samples amplified inefficiently with gSCA compar

258 P and qRT-PCR assays in detecting the dengue viremic samples.

259 All 12 HBV genomes derived from highly viremic sera (5 x 10(9) to 5.7 x 10(9) copies of viral g

260 The number of detected viremic seronegative infections was combined with the du

261 ive seronegative children and 5 seropositive viremic siblings had functionally viable PBMCs.

262 ol of central memory CD4(+) T lymphocytes in viremic SIV-infected sooty mangabeys and protect against

263 um of outcomes, including rapid progression, viremic slow progression, and elite control.

264 luding the blood, suggesting that there is a viremic stage during infection.

265 is activity, HBeAg seroconversion, and a low viremic state earlier than those carrying wild-type HBV.

266 re compared between controllers (n = 33) and viremic subjects (n = 27) using overlapping peptides, ma

267 -7 signaling in cells from both HIV-infected viremic subjects and healthy control subjects.

268 , and decreased levels of BTLA expression in viremic subjects compared to aviremic subjects and healt

269 gous plasma viral sequences from both EC and viremic subjects frequently harbored the typical cytotox

270 GBV-C-viremic subjects had significantly reduced CD4(+) and CD

271 s-clade neutralizing activity in plasma from viremic subjects were also assessed.

272 Compared with HCV seronegative subjects, HCV viremic subjects were at increased risk for stage 3 CKD

273 ignificantly lower GBV-C RNA levels than did viremic subjects without E2 antibody.

274 0 B57/B*5801-positive subjects (23 EC and 27 viremic subjects).

275 In viremic subjects, combined PD-L1/IL-10Ralpha blockade re

276 Within viremic subjects, the total IgG level correlated directl

277 eceptor+ NK cells were stable or elevated in viremic subjects, while the numbers of CD3-/CD56+/CD94+

278 uses and clinical confirmation of a critical viremic threshold for vascular delivery and intratumoral

279 (-/-) mice infected with LCMV Cl 13 remained viremic throughout life from defects in the adaptive ant

280 ce as well as the relationship of disease to viremic titer remain unclear due to wide variation in st

281 Among the 20 viremic, treatment-naive subjects studied, the only 5 su

282 h a low level of viremia, with 14 additional viremic units detected by prospective testing of individ

283 Of all the viremic units detected, 5 percent were detected only by

284 In 15 viremic, untreated patients, compared with 8 treated, vi

285 In contrast, highly viremic, unvaccinated controls did not develop detectabl

286 ruses a concern exists, that spillovers from viremic vaccinees could result in introduction of geneti

287 y with serum or intestinal contents from the viremic virulent HRV-inoculated pigs developed diarrhea,

288 The infectivity of sera from the viremic virulent HRV-inoculated pigs was confirmed by in

289 .1) million noninstitutionalized people were viremic, which dropped to 1.9 (95% CI, 1.4-2.6) million

290 ble PVLs (<150 copies/mL), and 77 (72%) were viremic with a median PVL of 5450 copies/mL (interquarti

291 61 of the samples (46.9%) were classified as viremic with qRT-PCR.

292 th HCV-seronegative participants and (2) HCV-viremic with successfully treated nonviremic patients.

293 Animals became viremic within 4 days and succumbed to infection between

294 >60% decreased risk of AIDS for HCV-positive viremic women and HCV-negative women.

295 HCV-positive viremic women had a statistically significantly higher p

296 The AIDS risk was greater among HCV-positive viremic women in the highest tertile compared with the l

297 ned for anti-HCV antibodies and HCV RNA, and viremic women were tested for quantitative HCV RNA at 3,

298 n with HIV coinfection, and 407 HCV-positive viremic women with HIV coinfection (median follow-up tim

299 HCV-positive viremic women with HIV coinfection who have high levels

300 r children born to HCV antibody-positive and viremic women, aged >/=18 months, separately by maternal